Last reviewed · How we verify
NCT04188249
Effectiveness and Adherence of Golimumab in Rheumatoid Arthritis
trial testing Golimumab in Arthritis, Rheumatoid in 200 participants. Status unknown.
1 March 2021
Quick facts
| Lead sponsor | Peking Union Medical College Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 1 July 2019 |
| Primary completion | 1 March 2021 |
| Estimated completion | 1 March 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- Golimumab (GOLIMUMAB) — full drug profile →
Conditions studied
- Arthritis, Rheumatoid — all drugs for Arthritis, Rheumatoid →
Sponsor
Peking Union Medical College Hospital
Who can join
Adults 18 to 80, any sex, with Arthritis, Rheumatoid. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This will be a prospective, observational, single-arm, registry study based on data received from Chinese Registry of rheumatoid arthritis (CREDIT) database to register 200 Chinese RA patients treated with golimumab in one year. Patient characteristic, clinical effectiveness and drug adherence of golimumab will be evaluated.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04188249
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Golimumab
Trials testing the same drug.
- NCT05960578 — Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study · Phase 2 · active not recruiting
- NCT05242484 — A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerati · Phase 2 · active not recruiting
- NCT05242471 — A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's · Phase 2 · active not recruiting
- NCT05164198 — REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST) · Phase 4 · unknown
- NCT05071664 — A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis · Phase 2 · completed
Other recruiting trials for Arthritis, Rheumatoid
Currently open trials in the same condition.
- NCT07176390 — A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014) · Phase 2 · recruiting
- NCT06842316 — Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases · recruiting
- NCT06528431 — Design and Evaluation of an Individualized Biodrug Tapering Strategy Based on Biodrug Dosage: the MONITORA Study · Phase 4 · recruiting
- NCT06492200 — Impact of a High-fiber Diet on the Microbiome and Disease Activity in Patients With Rheumatoid Arthritis · NA · recruiting
- NCT06246123 — A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants · recruiting
Other Peking Union Medical College Hospital trials
Trials by the same sponsor.
- NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
- NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
- NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
- NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
- NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04188249 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
- Last refreshed: 5 December 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04188249.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing